Safety and Efficacy of Asimadoline (TP0052) in Patients With Vasomotor Symptoms (VMS). | MicrobiomeTrials← Back to trialsNCT07042516
Safety and Efficacy of Asimadoline (TP0052) in Patients With Vasomotor Symptoms (VMS).
RecruitingPHASE2INTERVENTIONAL
Trial Details
Start: 2025-08-13Est. Completion: 2027-10-31
Enrollment target: 120 participants Locations- Department of Gynecology & Obstetrics, Emory University School of Medicine, Atlanta, Georgia, United States
Other microbiome trials you might be interested in
Vasomotor Symptoms Associated With MenopauseHealthy Volunteers
The purpose of this study is to evaluate the effects of single and multiple doses of ABCL635 administered by subcutaneou…
Calgary, CanadaEst. completion Feb 2027
Risk ReductionBreast Cancer
Women at risk for development of breast cancer and experiencing vasomotor menopausal symptoms (hot flashes) will be rand…
Duarte, United StatesEst. completion Oct 2026
Phase 3
Recruiting
One of the standard treatments for women with breast cancer is hormone therapy, but this treatment can cause hot flashes…
Sarnia, CanadaEst. completion Jun 25, 2026